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Despite the high burden of Plasmodium vivax malaria in South Asian countries, the genetic
diversity of circulating parasite populations is not well described. Determinants of anti-
malarial drug susceptibility for P. vivax in the region have not been characterised. Our
genomic analysis of global P. vivax (n= 558) establishes South Asian isolates (n= 92) as a
distinct subpopulation, which shares ancestry with some East African and South East Asian
parasites. Signals of positive selection are linked to drug resistance-associated loci including
pvkelch10, pvmrp1, pvdhfr and pvdhps, and two loci linked to P. vivax invasion of reticulocytes,
pvrbp1a and pvrbp1b. Significant identity-by-descent was found in extended chromosome
regions common to P. vivax from India and Ethiopia, including the pvdbp gene associated with
Duffy blood group binding. Our investigation provides new understanding of global P. vivax
population structure and genomic diversity, and genetic evidence of recent directional
selection in this important human pathogen.
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P lasmodium vivax is now the leading cause of humanmalaria outside of sub-Saharan Africa1, where intensivedisease-control interventions prioritising the control of
P. falciparum, have had less impact on reducing the transmission
of P. vivax2. Despite an estimated overall reduction of 61.0% in
the burden of vivax malaria worldwide since 2000, there were 6.4
million cases reported in 20191. Some countries have seen recent
worrying plateauing in rates of case decline, or even increases
(e.g., Papua New Guinea, Sudan, Yemen), partly associated with
regions affected by political and economic instability, making the
support of effective malaria control strategies difficult2. Further,
drug resistance is potentially hindering malaria elimination.
Resistance of P. vivax to chloroquine was first reported in 2003 in
Papua New Guinea, and is now present in many P. vivax endemic
countries3. As chloroquine susceptibility falls in P. vivax from
these regions, the rates of treatment failure and relapse are
increasing1. P. vivax has also developed resistance to the anti-
folate drug combination sulfadoxine-pyrimethamine (SP), and
possibly other antimalarial drugs such as mefloquine, used for
P. falciparum where the two species are sympatric. As a result,
artemisinin-based combination therapy (ACT) is now recom-
mended for treating vivax malaria1,4. Other control measures
which are traditionally effective against other Plasmodium para-
sites (e.g., P. falciparum) have proven to be less effective against
P. vivax5 due to its ability to form dormant liver-stage parasites6.
These hypnozoites cause delayed blood-stage relapses, but can be
cleared from the liver with primaquine or tafenoquine treatments,
although both regimens can cause severe haemolysis in indivi-
duals with G6PD deficiency7.
Countries in South Asia, including India, Afghanistan and
Pakistan, account for nearly two-thirds of the total estimated
P. vivax malaria cases globally, but there is little understanding
of the parasite ancestry, genomic diversity and underlying fac-
tors governing transmission and drug resistance. Similarly,
Eastern Africa accounts for a further 8% of the global cases1, but
only in southern Ethiopia has genomic diversity been studied8.
This contrasts with sequencing studies in South East Asia and
South America, where genome-wide analyses have provided
evidence of clustering of P. vivax in geographically distinct
subpopulations, and for selective pressure on genetic regions
encompassing some P. falciparum orthologous drug-resistance
loci, including pvdhps and pvdhfr genes linked to SP9–11.
Applying such population genetic approaches to identify
determinants of drug resistance is important, because the
understanding of biological susceptibility mechanisms including
frontline chloroquine is poor; in part, hampered by the inability
to long-term culture P. vivax parasites in the laboratory.
Further, studies of in vivo drug efficacy are complicated by the
difficulty of determining whether parasite reappearance comes
from a new infection, recrudescence after treatment, or from
relapse due to hypnozoite activation.
Whole-genome sequencing analysis has provided insights into
P. vivax populations approaching elimination, which typically
undergo a transition from high recombination rates and wide-
spread intermixing, to clonal expansions with reduced genetic
diversity12. Tracking this evolution of transmission patterns and
inferring the geographical origin of isolates is aided by newly
designed molecular barcodes13. Complementing these barcodes
with South Asian and East African markers in putative drug-
resistance genes will further assist infection control. Given the
expansive P. vivax populations in the South Asia region are lar-
gely absent from population-based genomic studies, we have
sequenced >118 P. vivax isolates in UK travellers with unam-
biguous travel histories returning from Bangladesh, India, Paki-
stan and Afghanistan. In general, travellers returning from
malaria-endemic countries tend to have monoinfections, and
provide an opportunity to investigate infections and drug efficacy
in a potentially high-risk group14. The inclusion of these new
South Asian parasite whole-genome sequences, together with new
data generated from travellers to three East African countries
(Eritrea, Sudan and Uganda) and previously published data,
enables the largest study of P. vivax genomics to date (n= 558).
By introducing data from little-studied geographic sources, our
analysis provides expanded insights into the global ancestry,
genomic diversity and population structure of P. vivax. We
sought evidence that the substantial P. vivax populations of South
Asia bear specific signals of selection in their genomes, and may
harbour geographically distinct variants of drug susceptibility-
associated loci and genes encoding red cell invasion proteins
considered vaccine candidates. This knowledge can potentially
inform the control of a disease with a high burden in this heavily
populated region.
Results
Genome data and multi-clonality. A total of 388,933 high-
quality SNPs were identified in the non-hypervariable regions in
the genome of P. vivax. The final dataset comprised 558 isolates
from 25 different countries (Supplementary Data 1), which were
assigned into approximate regional groups: South Asia (n= 92;
Afghanistan, Bangladesh, India, Sri Lanka, Pakistan; 89 returning
travellers), East Africa (n= 50; Eritrea, Ethiopia, Madagascar,
Sudan, Uganda; 25 returning travellers), South America (n= 146;
Brazil, Colombia, Guyana, Peru, Mexico; 3 returning travellers),
South East Asia (SEA; n= 186; Cambodia, China, Laos, Myan-
mar, Thailand, Vietnam), and Southern SEA (n= 84; Malaysia,
Papua New Guinea, Indonesia, The Philippines; 1 returning tra-
veller). A total of 118 P. vivax isolates from travellers entering the
UK with unambiguous histories were sequenced de novo, cov-
ering five countries that have not previously undergone whole-
genome sequencing.
Multi-clonality, as measured by within-sample diversity (FWS
metric >95%), was more common among SEA non-traveller
isolates (69/186; 37.1%), than among non-traveller isolates from
South America (24/146; 17.0%) or returning traveller isolates
from both South Asia (15/88; 17.0%) and East Africa (3/25;
12.0%) (S1 Figure). This observation would suggest a lower
proportion of superinfection and/or co-transmission of multi-
ple strains in returning travellers, likely to simply reflect a
restricted period of exposure to potentially infected Anopheles
mosquitoes.
P. vivax isolates from South Asia and East Africa are distinct
subpopulations. A SNP-based neighbour-joining tree revealed
that South Asian and East African isolates occupy distinct posi-
tions as independent subpopulations within a global setting
(Fig. 1). An admixture ancestral analysis suggested that these two
subpopulations are amongst seven others, which represent iso-
lates from South America (three subpopulations; Mexico, Peru,
Colombia/Brazil), SEA (1), and Southern SEA (3). Further, some
isolates in both the East African and the SEA subpopulations,
especially Thailand and Myanmar, share this South Asian
ancestry (Fig. 1). This population structure was also supported by
principal components analysis (PCA) (Fig. 1), where analysis of
South Asian isolates alone highlighted a further geographical
separation of Indian isolates from Pakistan and Afghanistan’s
subpopulations (S2 Figure); whilst in East African isolates, there
was separation for isolates from travellers returning from Uganda
compared to other East African countries. Furthermore, isolates
from Eritrea and Sudan seemed to cluster together and mostly
separated from Ethiopian isolates (S2 Figure).
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Analysis of IBD at the country level reveals similar regions of
homology in India as in Ethiopia. Analysis of identity-by-
descent (IBD) at the country level was performed in order to
understand the chromosome-level structure in the subpopula-
tions. The isolates obtained from returning travellers from India
(median: 0.024), Pakistan (median: 0.013) and Afghanistan
(median: 0.013) presented lower fractions of pairwise IBD overall
than other isolates sampled in more geographically limited
regions, such as Mexico (median: 0.23) or Malaysia (median:
0.33); but similar to other subpopulations in SEA, such as Thai-
land (median: 0.026) or Cambodia (median: 0.017) (S3 Figure). A
genome-wide analysis of IBD fractions using sliding windows of
10 kbp revealed differences at the country level (S4 Figure and
Supplementary Data 2). The regions with the highest IBD frac-
tions across all three South Asia subpopulations included a seg-
ment of chromosome 10 encompassing the Myosin B protein
(average IBD fraction: 0.074), the liver-specific protein 2 (LISP2)
on chromosome 3 (0.064) and a cluster of loci spanning the
pvmsp1 gene located on chromosome 7 (0.064) (Supplementary
Data 2). IBD fraction signals specific to Indian isolates were
identified in three regions at the end of chromosomes 2, 4 and 6,
presenting a degree of overlap with the signals observed in
Ethiopia; these regions included the pvmrp1 gene (chr. 2;
150–160 kbp), a cluster of genes including PHIST proteins (chr. 4;
930–970 kbp) and the pvdbp gene and its neighbouring regions
(chr. 6; 970–1010 kbp). Three Afghanistan-specific signals were
observed, one on chromosome 1 (710–740 kbp) spanning six
genes, and two on chromosome 11, including 630–660 kbp,
spanning 7 genes (e.g., pvpk5), and 1050–1070 kbp spanning 6
genes (e.g., pvsms1 and pvsms2). One signal specific to Pakistan
corresponded to a region on chromosome 8 (280– 300 kbp)
spanning five genes, including pvgbp2 and pvtmem147. These
regions could be candidates for inclusion in molecular barcodes
for P. vivax.
Population differentiation in putative drug resistance and
mosquito-related genes. The SNPs underlying differences
between subpopulations were identified using a fixation index
(FST) analysis. The FST distributions between putative drug
resistance and other loci were different between SEA and South
Asian or East African populations (Wilcoxon P < 0.012) (S5
Figure). The number of SNPs found to be highly differentiating
(FST > 0.8) varied in number, with South Asia (n= 5) and SEA
(n= 6) having much less than the other regions (Southern SEA
28; East Africa 43; South America 136) (Table 1 and Supple-
mentary Data 3). There was high population differentiation in
(putative) drug-resistance genes in SEA, particularly in pvdmt1
(S310R and V217I) and pvmrp1 (L1207I, V879 and T234M); for
East Africa, South Asia and South America there was high dif-
ferentiation in members of the CRMP gene family (pvcrmp1, 3
and 4), implicated in mosquito transmission. Mutations in genes
associated with mosquito stages of the parasite life cycle differ-
entiated South Asian (pvs28 and pvs47) and South American
(pvs47, pvs48/45) populations, likely linked to differences in
species of mosquito vectors, where pvs47 has a role in parasite-
mosquito interactions and its haplotypes present a marked geo-
graphical population structure15. Other loci with mutations with
high FST in South Asia include the PVP01_0514700 gene (FST=
0.95) which has an unknown function, and the protein disulfide































Fig. 1 Population structure analysis using the whole set of 558 P. vivax isolates. Analysis of the whole set supports one unique non-differentiated
subpopulation for the South Asian isolates. a Neighbour-Joining tree for the 558 isolates, constructed using a genetic distance based on 388,933 high-
quality SNPs, and branches coloured based on (b); b ADMIXTURE prediction of a subpopulation (K= 9) visualised using a bar plot. c Principal Components
Analysis (PCA) plot of the 558 isolates, with colours based on (b). d Neighbour-Joining tree for South Asia (India 36, Pakistan 32, Afghanistan 22), and
East Africa (Ethiopia 29, Eritrea 12, Sudan 5, Uganda 3, Madagascar 1). Thailand isolates (128) were used as a representative population from South East
Asia. Tree branches are coloured based on the assignment of the subpopulation from (e). e An ADMIXTURE bar plot illustrating the population structure
(K= 4), highlighting a distinction between South Asian countries and Thailand, and East Africa and Thailand. The plot also highlights a degree of mixing
between East African and South Asian populations. f PCA plot using the same data as in (d).
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mutations occurred in the pvclamp gene linked to parasite
motility, and PVP01_1444400 (max. FST= 0.91) with unknown
function; whereas, there was a cluster of mutations on chromo-
some 11 surrounding PVP01_1129700 (max. FST= 0.99), which
was South American-specific.
Identification of mutations in P. vivax drug-resistance candi-
date orthologues. With strong population-differentiating effects
implicated in Plasmodium drug susceptibility loci in SEA, we
identified non-synonymous (NS) mutations in P. vivax genes of
interest and assessed their frequency across all regions: pvcrt
(4 NS), pvdhfr (17), pvdhps (21), pvkelch12 (PVP01_1211100;
encoding a protein with 98% sequence identity with pfK13 in the
306 amino acid propeller domain; 6 NS), pvmdr1 (27), pvmrp1
(41) and pvpm4 (plasmepsin4; 3) (Supplementary Data 4). The
majority of these mutations had low frequency across any region
(60/119 mutations with maximum regional frequency <3%),
including none in pvcrt or pvkelch12, suggestive of their lack of
association with drug resistance in these populations. Of the four
mutations found in pvcrt, two occurred in SEA (P38L Thailand;
R121K Thailand/Cambodia), one in Mexico (E207Q), and one in
Pakistan (P16L; n= 1). Similarly, for pvkelch12, two mutations
outside the propeller domain were observed in South Asia (I6M,
n= 2, India and Pakistan; N25I, n= 2, Pakistan and Thailand).
No mutations in the pvcrt or pvkelch12 genes were identified in
East Africa. Finally, in the pvpm4 gene, orthologous to piper-
aquine resistance-associated pfpm4 in P. falciparum, only one
mutation (I165V) was present across all regions including both
South Asia (7.7%) and East Africa (24.5%), and two other
mutations were present only in Papua New Guinea.
Mutations in pvdhfr (PVP01_0526600) and pvdhps
(PVP01_1429500) genes in the anti-folate pathway are thought
to contribute to SP drug resistance, although there are very few
published studies that associate genotypes of these loci with anti-
folate susceptibility phenotypes16–18. We observed several pvdhfr
mutations (F57L, F57I, T61M, N117T) in SEA or Southern SEA,
but these were absent from South Asia and East Africa (Table 2).
An alternative amino acid substitution (N117S) was observed
more prominently in South Asia (62.2%), although also present in
Table 1 SNPs with high FST ( > 0.8) that differentiate P. vivax isolates from South East Asia (SEA), East Africa and South Asia
regions.
Region Chr. Position Ref. Alt Effect* AA change Gene name FST**
SEA 2 155305 G T Non Syn L1207I pvmrp1 0.83
SEA 2 156287 C A Syn V879 pvmrp1 0.82
SEA 2 158223 G A Non Syn T234M pvmrp1 0.81
SEA 14 1070933 A T Non Syn S310R pvdmt1 0.86
SEA 14 1071214 C T Non Syn V217I pvdmt1 0.90
South Asia 5 286241 A T Non Syn I83F PDI8 0.83
South Asia 5 618291 T G Non Syn F165V PVP01_0514700 0.95
South Asia 6 668360 G T Non Syn T65K P28 0.83
South Asia 12 323703 G C Non Syn S57T P47 0.81
South Asia 13 336960 C A Non Syn T1455K CRMP3 0.81
East Africa 4 308246 A G Intron – CDPK1 0.83
East Africa 4 401595 C T Syn Y670 ACS9 0.81
East Africa 4 401608 T C Syn L675 ACS9 0.85
East Africa 4 401622 C T Syn N679 ACS9 0.90
East Africa 5 722792 T G Non Syn I172L PVP01_0517200 0.86
East Africa 5 1067476 C T Non Syn E158K PVP01_0526300 0.87
East Africa 5 1071079 T G Intron – PVP01_0526400 0.92
East Africa 6 646355 C T Non Syn M236I CLAMP 0.96
East Africa 6 646864 C T Non Syn D67N CLAMP 0.88
East Africa 6 661527 C G Non Syn S273C RPN9 0.85
East Africa 7 499047 T G Non Syn I1234S CRMP1 0.93
East Africa 7 507890 T A Syn P582 PVP01_0709900 0.90
East Africa 7 509284 C T Non Syn D118N PVP01_0709900 0.96
East Africa 7 509311 A G Non Syn Y109H PVP01_0709900 0.95
East Africa 7 509312 G A Syn L108 PVP01_0709900 0.95
East Africa 7 514538 A G Syn L14 PVP01_0710100 0.91
East Africa 7 525785 T C Syn A1270 PVP01_0710500 0.80
East Africa 7 556907 C G Non Syn M709I PVP01_0711500 0.89
East Africa 11 917226 A T Non Syn F1138L PK4 0.87
East Africa 11 1075544 C G Non Syn S455R PVP01_1124700 0.88
East Africa 12 1869662 T C Non Syn V414A PVP01_1245200 0.84
East Africa 13 334457 A G Non Syn K621E CRMP3 0.86
East Africa 13 334917 T G Non Syn M774R CRMP3 0.90
East Africa 13 610100 C A Non Syn K841N PVP01_1313400 0.89
East Africa 14 1296340 T C Syn S205 PPM5 0.81
East Africa 14 1923223 G A Non Syn P504S PVP01_1444400 0.81
East Africa 14 1923997 T G Non Syn M246L PVP01_1444400 0.91
East Africa 14 1923998 C G Syn T245 PVP01_1444400 0.91
East Africa 14 1924051 T C Non Syn T228A PVP01_1444400 0.91
East Africa 14 1924658 C T Syn E25 PVP01_1444400 0.85
AA amino acid, *Non Syn non-synonymous mutation, Syn synonymous mutation, Inter intergenic region, Start lost start codon lost.
**Within Region vs. other isolates.
See Supplementary Data 3 for all regional comparisons.
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Table 2 Common mutations (allele frequency %) in putative drug-resistance genes.










pvdhfr 1077510 N50I 7.1
pvdhfr 1077530/2 F57I 56.2
pvdhfr 1077530/2 F57L 4.3 76.5
pvdhfr 1077534 K58R 8.8
pvdhfr 1077535 S58R 34.5 88.0 67.9 100 62.2
pvdhfr 1077543 T61M 64.9 36.5
pvdhfr 1077711 N117T 0.7 64.1 72.6
pvdhfr 1077711 N117S 62.2 6.3 20.3 9.5
pvdhfr 1078090 D243E 3.6
pvdhfr 1078180 N273K 10.7
pvdhps 1270256 M601I 6.6
pvdhps 1270401 A553G 11.0 0.6 67.6 54.1
pvdhps 1270524 K512M 3.8
pvdhps 1270683 D459A 3.3
pvdhps 1270793 C422W 15.3
pvdhps 1270911 G383A 86.7 68.0 47.2 3.8 32.1
pvdhps 1270914 S382C 10.6
pvdhps 1270915 S382A 21.1
pvdhps 1270966 F365L 4.4
pvdhps 1271444 M205I* 72.0 59.2 100 8.2
pvdhps 1271634 E142G* 64.0
pvdhps 1271664 E132G* 38.8
pvmdr1 478789 L1449I 7.8
pvmdr1 478955 K1393N 11.2 2.0 10.8 1.2
pvmdr1 479329 T1269S 10.1
pvmdr1 479908 L1076F 2.2 88.1 33.5 1.2
pvmdr1 480207 F976Y 97.8 46.0 89.9 68.7 11.9
pvmdr1 480412 L908M 13.5
pvmdr1 480552 A861E 4.4 3.8
pvmdr1 480601 L845F 14.3 8.7 2.4
pvmdr1 480846 A763V 3.8
pvmdr1 481042 S698G 59.3 38.0 100 0.5
pvmdr1 481595 S513R 35.6 72.0 0.6 23.2
pvmdr1 481636 D500N 17.3
pvmdr1 481908 T409M 11.1
pvmdr1 482473 V221L 18.9
pvmrp1 153954 N1657S 30.1
pvmrp1 154065 I1620T 4.7
pvmrp1 154107 A1606D 7.5
pvmrp1 154108 A1606T 7.6
pvmrp1 154168 H1586Y 9.3 28.9 3.8
pvmrp1 154216 D1570Y 3.5
pvmrp1 154294 V1544I 8.5
pvmrp1 154350 T1525I 6.3
pvmrp1 154492 I1478V 20.3 23.5 15.4
pvmrp1 154668 G1419A 23.4 16.7 33.8
pvmrp1 154747 D1393Y 18.3 4.9 0.5
pvmrp1 154831 L1365F 3.5
pvmrp1 154843 L1361F 3.0 0.5
pvmrp1 155080 L1282I 9.6
pvmrp1 155305 L1207I 85.4
pvmrp1 155871 C1018Y 6.1
pvmrp1 156208 E906Q 42.6 48.6 24.8 4.3 9.4
pvmrp1 157300 K542E 14.1 2.5 1.4
pvmrp1 158148 R259T* 39.3 50.0 13.3 0.5
pvmrp1 158223 T234M 84.0 1.2
pvpm4 1802108 I165V 7.7 24.5 66.3 56.2 22.6
Allele frequency bolded if >50%; South Asia (Afghanistan, Bangladesh, India, Sri Lanka, Pakistan); East Africa (Eritrea, Ethiopia, Madagascar), South America (Brazil, Colombia, Guyana, Peru, Mexico);
SEA (Cambodia, China, Laos, Myanmar, Thailand, Vietnam); Southern SEA (Malaysia, Papua New Guinea, Indonesia, The Philippines); * in the HPPK-coding part of the bifunctional gene.
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South America (20.3%) and East Africa (6.3%). The S58R
resistance allele was present across all regions, being fixed in
SEA, common in East Africa (88.0%), but at lower frequency in
South Asia (34.5%), where there was heterogeneity between
countries (Pakistan and Afghanistan <19.8% vs. India 71.4%).
Three mutations specific to South Asia were identified in pvdhfr
(N50I, D243E and N273K) at low frequencies (range: 3.6–10.7%).
For pvdhps, previously described mutations A553G and A383G
were observed in high frequency in SEA (67.6% and 96.3%) and
Southern SEA (54.1% and 68.9%), with lower frequencies in
South Asia (11.0% and 13.3%) and East Africa (0% and 32.0%).
Six mutations were unique to the South Asian region
(M601I, D459A, M367L, F365L, I337V and E106D; < 7%) all
present in low frequency across any of the three main countries
(<13%). A further two mutations (L534I and E142G) were
observed only in East Africa, with L534I exclusively in Uganda
and E142G present across all four constituent countries. Based on
in silico protein modelling, eight mutations in the PVDHFR
(N50I, F57I/L, S/K58R, T61M, N117T/S) and four in the
PVDHPS (A553G, G383A, S382C/A) are within a distance of
10 Å of the drug-binding site and could be expected to change the
affinity of the drugs and proteins (Supplementary Data 5 and S6
Figure).
Pvmdr1 F1076L and Y976F mutations have been implicated in
reduced chloroquine susceptibility, and F1076L was observed
with high frequency across all regions (>66%; East Africa 100%,
South Asia 97.8%) with the exception of South America (11.9%).
The Y976F mutation was at high frequency in Southern SEA
(88.1%) and also present in East Africa (54.0%) and SEA (32.3%),
and at lower frequency in South Asia (2.2%) and South America
(10.1%). Two mutations (S698G, S513R) were found at higher
frequency in South Asia and East Africa (>35%) than in SEA and
Southern SEA (< 1%), with S698G fixed in South America
(100%). The N1657S mutation is found only in Malaysia. Eight
mutations were observed in South Asia only, but only three
(L1449I, T1269S, T409M) were common (>7%) (Table 2).
In the candidate pvmrp1 gene, the high frequency of L1207I
and T234M mutations exclusively in SEA (> 83%) coincided with
the high population differentiation FST results (Table 1). Several
mutations (I1478V, G1419A, D1393Y, E906Q, K542E, and
R259T) were more frequent in isolates from South Asia and
Africa, compared to Southern SEA and SEA. The I1478V,
D1393Y, E906Q and R259T mutations were present in modest
frequency in South American isolates (range: 4.9–48.6%). The
most frequent mutations in East Africa (Ethiopia 51.9%) and
South Asia (India ~45%), included R259T and E906Q with
relatively low frequency (<10%) in both Southern SEA and SEA.
Mutation D1393Y was found predominantly in South Asian
isolates (18.3%), and G1419A was found in moderate frequency
across South America (33.8%), South Asia (23.4%) and East
Africa (16.7%) (Table 2). The comparison of orthologous amino
acid positions (pfmrp1 1390 is pvmrp1 1298; pfmrp1 1466 is
pvmrp1 1374) revealed the proximity of pvmrp1 mutations (e.g.,
D1393Y, G1419A) to established drug-resistance phenotype
causing mutations in P. falciparum in the vicinity of the 2nd
ABC transporter domain (S7 Figure). This relationship highlights
the potential role of the pvmrp1 mutations in driving drug
resistance in P. vivax in an orthologous manner to the one
observed in P. falciparum, whose function could be tested in
in vitro assays using a P. knowlesi model19.
Regions under selection in South Asian and East African
subpopulations. Given the potential for population differentia-
tion in putative drug-resistance genes, such as pvmrp1, we sought
through a genome-wide analysis to identify if these or other loci
are involved in selective sweeps. Analysis of positive selection
within subpopulations was assessed using the integrated haplo-
type score (iHS) at a country and region level, for populations
with at least ten isolates. We found regions containing the pvmrp1
in SEA, the antigenic and potential vaccine targets pvmsp4/5
genes in SEA, South America and Papua New Guinea; as well as
further regions upstream of the pvdhfr gene, a region surrounding
the MSP7-like cluster of genes on chromosome 12 in South
America, and a cluster of PHIST exported genes on chromosome
14 in Papua New Guinea (all P < 10−4) (Supplementary Data 6
and 7).
For the South Asian subpopulations, ten chromosomal regions
had multiple SNP hits (all P < 10−4), which included clusters
surrounding pvmrp1, pvcrmp2, antigenic targets (pvmsp1, pvmsp2,
pvmsp4/5), uncharacterised genes on chromosome 6
(PVP01_0620400 to _0621000), reticulocyte-binding and invasion
loci (pvrbp1a/b), the pvdhfs gene that encodes the bifunctional
enzyme dihydrofolate synthase/folylpolyglutamate synthase
(upstream of DHFR in the folate biosynthesis pathway), and
uncharacterised exported proteins on chromosome 14
(PVP01_1427400 to _1427800) (Fig. 2). In East Africa, selective
sweeps were detected around pvmsp4/5, the pvabcg2 transporter
and several P. vivax ApiAP2 transcription factors on chromo-
somes 12, 13 and 14 (Fig. 2). Country-level analyses reinforced
the pvmsp4/5 gene findings in Pakistan, Ethiopia and Eritrea
(P < 1 × 10−8) (S8 Figure and Supplementary Data 6). In the
isolates sourced from India, the strongest evidence for iHS sweeps
were on chromosomes 11 (PVP01_1126100 to _1126500) and 14
(PVP01_1469900 to _1470700) which included tryptophan-rich
protein-coding genes (e.g., pvtrag23/24; P= 1 × 10−11). Similarly,
for the isolates from Afghanistan, the most significant SNPs were
found in a cluster of exported proteins on chromosome 8 (P < 1 ×
10−10), as well as a region surrounding the pvkelch06 (P= 1 ×
10−6), being orthologous to the artemisinin susceptibility-related
pfkelch10 gene20,21.
We identified evidence of geographically distinct signals of
selection using the Rsb metric in 34 candidate loci with at least
three significant SNPs (all P < 1 × 10−5) (Supplementary Data 7,
Fig. 2 and S9 Figure). By comparing South Asia to SEA, the most
significant hits were found proximal to drug-resistance candidate
regions (pvmrp1, pvdhfr and pvdhps; P < 1 × 10−7), as well as a
cluster including pvmsp4/5, and multiple genes on chromosomes 5
(PVP01_0525800 to _0526100), 11 (PVP01_1132900 to _1133600)
and 14 (PVP01_1401000 to _1401900). These results were
supported by individual South Asian country comparisons with
Thailand, including finding regions encompassing pvdhfr and
pvdhps genes (all P < 1 × 10−5), and pvmrp1 (India P < 1 × 10−15).
A comparison between South Asia and East Africa highlighted
pvdbp, involved in red blood cell invasion, and pvpk4 which is a
drug target for inhibiting PK4 kinase activity with potency across
species of malaria parasites. P. vivax isolates from Ethiopia
displayed evidence of selection on regions of chromosomes 2
(including pvmrp1) and 10 (spanning pvmsp8), but with
differential signals across South Asian population comparisons.
Between country comparisons within South Asia (Supplementary
Data 8, Fig. 2 and S10 Figure) using Rsb identified 71 regions (P <
1 × 10−5), and reinforced differences with isolates in India,
including genetic regions encompassing pvdbp, pvmrp1, pvmrp2,
sporozoite invasion-associated protein 2 (pvsiap2) and antigen
UB05 (all P < 10−11). Only 17 differences occurred between
Afghanistan and Pakistan, including pvcrmp2 and a high density
of exported proteins on chromosomes 6 and 8.
To study allele frequency distributions for individual genes
across populations, our analysis focused on the 4826 loci that had
at least five SNPs. Tajima’s D values were predominantly negative
(median: East Africa −0.314, South America −0.453, South Asia
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−0.759, Southern SEA −0.887, SEA −1.692), being most negative
in Thailand (median −1.545), consistent with a historical
population expansion of P. vivax or directional selection (S11
Figure). There were strong correlations between Tajima’s D
values within the same geographical region (Spearman’s correla-
tions: Afghanistan/India/Pakistan 0.490–0.572; Thailand/Cambo-
dia 0.507; Brazil/Colombia/Peru 0.250–0.308). Potential genes
under balancing selection inferred by high Tajima’s D values
(99.5 percentiles, Supplementary Data 9; values >2, Supplemen-
tary Data 10) included PHIST proteins (e.g., PVP01_0525100),
antigenic targets (e.g., pvCyRPA, pvmsp1, pvmsp5) and conserved
proteins of unknown function (e.g., PVP01_0620700,
PVP01_0203600). From above, the pathogenesis-related pvmsp5
locus also exhibited evidence of differential selection between
populations, more broadly, reflecting observed complex haplo-
type structures of different strains circulating in different
populations8.
Overall, the selection results reflect a picture of putative drug-
resistance loci (e.g., pvmrp1, pvdhfr and pvdhps) with population-
specific mutations within India, Afghanistan/Pakistan and Thai-
land, with signatures of directional selection. There was a modest
correlation between selection (Rsb) and population differentiation
(FST) statistics in regional comparisons for coding SNPs (Spear-
man coefficient: median 0.3; min. 0.2 Southern SEA vs. East
Africa or South America; max. 0.34 South Asia vs. East Africa),
where high values for both metrics included mutations in pvdhps,
pvdbp, p28/47 mosquito-related and the CRMP family of genes
(Supplementary Data 11).
Discussion
Despite South Asian countries contributing collectively to more
than half of the estimated P. vivax burden globally, the genomic
diversity and population structure of parasites in this region is
poorly understood. By evaluating samples from travellers
returning to the UK with vivax malaria within the past 3 years,
each with unambiguous travel histories to malaria-endemic
countries, we have provided whole genome sequencing data for
132 P. vivax isolates. This increases the available global dataset to
>700 isolates from at least 25 different countries. Analysis of
the levels of multiplicity of infection revealed that the sequenced
isolates from South Asian populations were less complex infec-
tions than has been reported for isolates from Thailand. This
result may arise because travellers are exposed to fewer infective
bites than people living permanently in a malaria-endemic region
over long periods of time, and therefore on average are infected
with fewer genotypes. By using either monoclonal or polyclonal
samples with only a major dominant clone, differences in the
multiplicity of infection linked to the source of parasite isolates
(traveller vs. endemic populations) are unlikely to have had a
major impact on our findings. However, we recognise that the
exclusion of polyclonal infections disproportionately from ende-
mic populations may have led to some underestimation of genetic
Fig. 2 Evidence of selective sweeps. Manhattan plots showing the genome-wide results of the iHS analysis on P. vivax from South Asia and East Africa
regions (a, b); Rsb analysis for P. vivax between geographical regions (c, d) and countries (e, f). Loci in critical regions (above red lines: orange points iHS
P < 1 × 10−5; purple points Rsb P < 1 × 10−5; two-sided tests) are reported in Supplementary Data 6 and Supplementary Data 7.
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diversity among these isolates compared to those from travellers.
The lower multiplicity of infection in travellers (e.g., from South
Asia) cannot be taken as an indication of lower transmission
intensity in the source country. Further, the returning traveller
samples were almost exclusively derived from passive sampling.
Several studies have suggested that parasites derived from pas-
sively detected symptomatic infections have similar genotypes to
actively detected asymptomatic infections22. These findings sug-
gest that the development of clinical symptoms may be more
attributable to host factors such as immunity and red blood cell
polymorphisms, than to intrinsic parasite factors resulting in a
higher multiplication rate. There are likely to be differences in
demographic (e.g., age, sex), and health characteristics (e.g., the
prevalence of comorbidities) in returning travellers compared to
resident populations, which might increase either susceptibility to
malaria infection or the risk of severe disease.
Population genetics analysis of the sequenced South Asian
isolates provides evidence of an ancestral parasite subpopulation
distinct from those in Africa, SEA and South America8,10–12. This
subpopulation encompasses India, Afghanistan, Pakistan, Ban-
gladesh and Sri Lanka, although isolates do share some features
with parasite genomes from East Africa and SEA. This distinct
characteristic is consistent with allopatric isolation by distance.
Furthermore, at an intra-regional level, a degree of genetic
separation was observed for isolates from India compared to
Afghanistan and Pakistan, which are indistinguishable from each
other, and an indication of parasite migration and gene flow
between these two countries. In East Africa, despite the small
sample size, a clear separation was observed for isolates from
travellers returning from Uganda compared to other East African
countries. Furthermore, isolates from Eritrea and Sudan seemed
to cluster together and were clearly separated from Ethiopian
isolates in the principal component analysis, although ADMIX-
TURE analysis did not reveal a separate ancestral population.
This observation is consistent with recent reports of genetic
diversity of P. vivax in Sudan using microsatellites23, but further
studies of P. vivax in this region are warranted, given the recent
history of cross-border refugee movements in the 20th and 21st
centuries. P. vivax isolates from travellers to Guyana and The
Philippines clustered near the South American and South East
Asian populations as expected. The consistency of results at the
geographic level combined with the observation that newly
sequenced Ethiopian isolates clustered together with previously
described Ethiopian sequences8 indicates that using returning
travellers can be a robust approach to study difficult-to-access
parasite populations. However, the typical lack of resolution of
geographic information below national or, at best, provincial
level, mean results should be backed up by future studies using
systematically collected population samples from endemic com-
munities in South Asia and East Africa.
Identity-by-descent (IBD) analysis was applied to further
understand the structure and selection within parasite
populations24,25. Analysis of the overall proportion of the genome
that presented evidence of IBD revealed that isolates obtained
from returning travellers displayed greater genetic diversity than
in some highly related sampling populations, in particular Mexico
and Malaysia. This result suggests that perhaps infections from
returning travellers may be more diverse because they are not
geographically defined by a given catchment area, whereas studies
of endemic malaria tend to be geographically centred, and thus
represent more coherent population samples. However, an
alternative explanation might be that the parasite populations in
Mexico and Malaysia are less diverse and highly related compared
to all populations, because of lower transmission, leading to
smaller effective population size. Our observed levels of IBD
among traveller isolates from each country of interest were
comparable to those of other populations such as Thailand or
Cambodia, further supporting this alternative explanation. The
genomic regions identified with a high proportion of IBD in
different subpopulations included the liver-specific protein 2
(LISP2) on chromosome 3, a region on chromosome 10 including
the Myosin B protein, and the pvmsp1 gene region located on
chromosome 7. A remarkable similarity was found between the
regions of high IBD in India and Ethiopia, including a strong
signal surrounding the pvdbp gene, the main invasion receptor
that interacts with the human Duffy antigen to invade red blood
cells. P vivax infections have now also been reported in Duffy-
negative individuals, and pvdbp gene alterations, such as dupli-
cations have been suggested as a mechanism contributing to this
adaptation8,26,27.
Population genetic analysis revealed genomic regions under-
going recent positive selection, including some encompassing loci
linked to drug resistance such as the pvmrp1, pvdhfr and pvdhps
genes11 in South Asia and other previously studied populations
(e.g., Thailand), as well as in the pvmsp4/5 regions on chromo-
some 4 for Ethiopia. Importantly, the analysis also revealed new
regions which had not been previously reported as presenting
with positive selection, including those surrounding the pvrbp1a
and pvrbp1b genes and the folate pathway gene pvdhfs in South
Asia. Furthermore, a region surrounding the pvkelch10 gene was
identified in Afghanistan as being under selection pressure, where
this locus is an orthologue to the pfkelch13 gene driving resistance
to artemisinin in P. falciparum28; although no record of artemi-
sinin resistance has been described in P. vivax currently, ACT
regimens are now commonly used to treat P. vivax infections in
many countries, reflecting guidance from the WHO29. Pheno-
typic information from in vivo ACT susceptibility studies linked
to further evaluation of genetic variants at these loci is now
needed to understand any selection acting upon the kelch pro-
peller domain proteins of P. vivax.
The pfmrp1 gene, encoding an ABC transporter transmem-
brane protein, is a potential multidrug-resistance candidate in P.
falciparum with mutations associated with reduced susceptibility
to SP (R1466K)30, chloroquine (F1390I)31,32, mefloquine
(T1007M)31 and pyronaridine (H785N)30–33. Previous popula-
tion genomic analyses of P. vivax populations in SEA and
Oceania found evidence that the pvmrp1 gene is under strong
selection10,11, and our study provides evidence for this in South
Asian isolates. Further, we found that pvmrp1 contributes to IBD
structure in other populations such as in Ethiopia. Previously
unreported mutations were observed in South Asian populations,
where pvmrp1 exhibited a high frequency of two non-
synonymous mutations (D1393Y and G1419A) compared to
other regional subpopulations, supporting the strong positive
selection signal. Furthermore, a comparison of the pvmrp1 and
pfmrp1 sequence similarity revealed that non-synonymous
mutations found in pvmrp1 specific to the South Asia region,
overlap with pfmrp1 locations residing between the ABC trans-
membrane and the second ABC transporter domains. Pfmrp1
mutations have been shown to confer resistance experimentally in
P. falciparum30,32. In the absence of a long-term P. vivax in vitro
culture system for validation, experimental strategies such as
orthologue replacement transgenesis in P. knowlesi, in which
P. vivax alleles of interest replace endogenous loci, can allow
in vitro assessment of drug susceptibility for these variants19.
Overall, this study has provided analyses of P. vivax population
structure and genomic diversity in three high burden South Asian
countries, and further advanced our understanding of the geno-
mic composition of P. vivax around the globe9,10. Despite some
limitations of sampling from returning travellers, including
reduced levels of the multiplicity of infection and therefore
disconnection from transmission intensity levels in the origin
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populations, this approach has delivered valuable genome-wide
data from otherwise uncharted P. vivax parasite populations. The
evidence presented relating to positive selection evidence in the
South Asian region for drug-resistance candidates such as pvmrp1
is founded on previously established findings in other endemic
regions8,10–12. The direct investigation of the phenotypes of gene
variants in P. vivax19, and identification of potential genetic
drivers of drug resistance using recent advancements in labora-
tory strategies such as orthologue replacement, is now possible.
Methods
Isolates and sequence data used for analysis. A total of 730 P. vivax isolates were
included in the study, including previously publicly available data8–10,12,13 (n= 598)
and newly sequenced (n= 132) isolates from imported UK cases with blood samples
sent to the Public Health England Malaria Reference Laboratory. After quality control,
the final dataset included 558 isolates from 25 countries spanning all the P. vivax
endemic regions (Supplementary Data 1): South America (n= 146; Brazil (31),
Colombia (34), Guyana (3), Peru (58), Mexico (20)), East Africa (n= 50; Eritrea (12),
Ethiopia (29), Madagascar (1), Sudan (5), Uganda (3)), South Asia (n= 92; Afgha-
nistan (22), Bangladesh (1), India (36), Sri Lanka (1), Pakistan (32)), South East Asia
(SEA; n= 186; Cambodia (32), China (1), Laos (2), Myanmar (9), Thailand (128),
Vietnam (14)) and the Western Pacific and southern South East Asia (Southern SEA;
n= 84; Malaysia (49), Papua New Guinea (25), Indonesia (9), The Philippines (1)).
These included both publicly available data (440/598; 73.6%) and newly sequenced
samples (118/132; 89.4%). Sequencing of the newly generated isolates (n= 132) used
DNA extracted from blood samples sourced from returning travellers to the UK from
endemic areas between 2017 and 2018 and was performed on an Illumina HiSeq 4000
platform. The 132 samples were sourced from travellers to Afghanistan (n= 26),
Bangladesh (n= 1), Eritrea (n= 11), Ethiopia (n= 6), Guyana (n= 3), India (n=
38), Pakistan (n= 35), The Philippines (n= 1), Sudan (n= 7) and Uganda (n= 4).
For the isolates from India, country regional level data were available for 32 isolates,
with 10 being fromMumbai, 8 from Gujarat, 7 from Goa and 7 from Punjab. The UK
National Research Ethics Service (Ref: 18/LO/0738) and LSHTM Research Ethics
Committee (Ref: 14710) provided approval for the project “Drug susceptibility and
genetic diversity of imported malaria parasites from UK travellers”. Informed consent
was obtained from all UK traveller study participants.
Raw reads mapping and bam file correction. The Illumina sequencing reads
were first filtered using trimmomatic (version 0.39) and the parameters: LEAD-
ING:3 TRAILING:3 SLIDINGWINDOW:4:20 MINLEN:36. Reads were then
mapped to the P. vivax P01 (PvP01; version 1) reference genome34 using bwa-mem
(version 0.7.12). The samtools35 (version 1.9) functions fixmate and markdup were
applied to the resulting BAM files. The GATK’s BaseRecalibrator and ApplyBQSR
functions were applied using a combined VCF file with SNPs identified in previous
datasets as being high quality and presenting a minimum allele frequency (MAF) >
5%11. A set of 730 improved BAM files was obtained. Alignment metrics were
calculated using the flagstats option within the samtools software.
Variant discovery and quality control. The discovery of SNPs and indels was
performed using GATK’s HaplotypeCaller (version 4.1.4.1) and followed recom-
mended best practice36. GATK was run with default parameters and using the
option -ERC GVCF. The GVCFs were validated using the GATK ValidateVariants
function, then imported into a GenomicDB using the GATK function Geno-
micsDBImport, and a combined VCF was created using the GATK Genoty-
peGVCFs function. A total of 1,384,569 SNPs were identified. Variants in
subtelomeric regions and internal vir genes regions were excluded. Subtelomeric
regions in the 14 chromosomal sequences were identified by mapping previously
published regions from P vivax Salvador I (PvSal1, version 1.0) into the PvP01
reference (Supplementary Data 12). Variants were then assigned a quality score
using GATK’s Variant Quality Score Recalibration (VQSR). VariantRecalibrator
was run using the previously mentioned dataset as a training set with a prior of
15.0. For SNPs we used the following parameters: -an QD -an FS -an SOR -an
DP–maxGaussians 4 and --mq-cap-for-logit-jitter-transform 70. ApplyVQSR was
then run using the parameter --truth-sensitivity-filter-level 99.0 to obtain a Variant
Quality Score Log-Odds (VQSLOD). Variants with a VQSLOD score < 0, repre-
senting variants more likely to be false than true, were filtered out.
A total of 172 isolates with >40% of SNPs missing genotype data, as a result of
poor sequencing coverage, were excluded from downstream analysis. The excluded
isolates consisted of 158 (91.9%) publicly available (Peru 38, Brazil 23, Colombia
22, Mexico 19, Papua New Guinea 19, Cambodia 10, Thailand 9, Vietnam 7,
Myanmar 6, Nicaragua 2, Panama 2, India 1) and 14 (8.1%) newly sequenced
traveller samples (Afghanistan 3, Eritrea 3, India 2, Pakistan 2, Sudan 2, Bangladesh
1, Guyana 1). Source countries with excluded isolates had other samples that
passed quality control, ensuring no loss in global representation. SNPs were then
processed to replace the genotype call in the VCF for a mixed call whenever the
secondary MAF was at least 20% in a given SNP on each individual sample. A
subset of only biallelic SNPs was also obtained from this matrix. The final matrix
consisted of 558 isolates (118 from travellers) and 388,933 high-quality SNPs.
Variants were annotated using snpEff (version 4.1)37 with the following options:
-no-downstream -no-upstream. A summary of the analysis pipeline applied is
presented in S12 Figure.
Multiplicity of infection. Multiplicity of infection (MOI) was assessed by grouping
isolate data at a country level and calculating the FWS score38, as well as at an
individual isolate level using estMOI(version 2.0)39. Only SNPs in coding regions
which were biallelic were used for the calculation of FWS. FWS was calculated using
the moimix (version 0.0.2.9001) package (https://github.com/bahlolab/moimix).
Population genetics. A principal component analysis (PCA) was performed on the
high-quality SNPs and isolates by calculating the pairwise genetic distance using the
Manhattan method. A neighbour-joining tree was obtained to represent these
similarities, and was generated using the ape package (version 5.4-1)40. A total of
135,954 high-quality SNPs with MAF > 1% were used to assess the population
structure within the ADMIXTURE (version 1.3.0) package, where the most likely
number of subpopulations (K) was obtained using cross-validation error 41. In order
to assess the SNPs driving the allele frequency differences between populations, we
identified high fixation index FST42 values using the PopGenome library (version
2.7.5) in R. Isolate populations were compared at both a regional and country level.
Positive and balancing selection and IBD analysis. Isolate populations at both
country and regional level with >10 isolates were screened for positive selection
using the rehh package (version 3.2.1) in R43. Isolates with FWS < 95% were excluded
from this analysis in order to use only monoclonal infections. EstMOI estimated
that MOI was 1 for the majority of evaluable included isolates, with less than thirty
displaying an MOI of 2, and for these, dominant clones had a relative abundance of
at least 90% in every case. Both the integrated haplotype score (iHS)44 for within-
population selection and Rsb for identification of selection between two
populations45 were calculated. Calls obtained from the P. cynomolgi data (Accession
number: DRR000476) were used as the ancestral states of the SNPs in our dataset12.
Critical regions were identified using a 10 kbp sliding window including at least
three SNPs with a P value <1 × 10−4 for iHS and a P value <1 × 10−5 for Rsb.
Tajima’s D was calculated at a country level using the package pegas (version 0.14)
in R for populations with >10 isolates and for genes with >5 SNPs. A negative
Tajima’s D value may indicate population size expansion and/or purifying selection.
Whilst a positive value may indicate a decrease in population size and/or balancing
selection. Identity-by-descent (IBD) screening was also performed at a country level
using the package hmmIBD (version 2.0.4)24 for populations with >10 isolates and
excluding isolates with FWS > 95%. Default parameters, including recombination
rate, were used and based on P. falciparum estimates24. The proportion of pairwise
comparisons for isolates presenting evidence of IBD was plotted by genome location
using a sliding window of 10 kbp.
Comparison of pvmrp1 and pfmrp1 genes. P. vivax orthologues of P. falciparum
genes are based on high levels of identity and similarity in the encoded amino acid
sequences46. The protein sequences for pvmrp1 and pfmrp1 genes were down-
loaded from PlasmoDB (https://plasmodb.org) with gene ID PF3D7_0112200 for
pfmrp1 and PVP01_0203000 for pvmrp1, and then aligned using the mafft protein
aligner (https://mafft.cbrc.jp/alignment/software/). Protein domains predictions
were also accessed through the PlasmoDB website.
Protein structural modelling. Protein structures for DHFR and DHPS were
downloaded from the Protein Data Bank (PDB) (https://www.rcsb.org/) (DHFR:
2BL9, DHPS: 5Z79). The structures were visualised and annotated using UCSC
chimera. Distance from the ligand was calculated using the mCSM-lig webserver
(http://biosig.unimelb.edu.au/mcsm_lig).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Protein structures for DHFR (2BL9) and DHPS (5Z79) were available from the PDB. All
raw sequence data is available from the European Nucleotide Archive (www.ebi.ac.uk/
ena; see Supplementary Data 1 for accession numbers). These data include samples from
the LSHTM returning travellers (PRJEB44419) and the MalariaGEN P. vivax Genome
Variation project (see ref. 10).
Code availability
All scripts use open source software (see “Methods”).
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